ProCE Banner Activity

ExpressPoints
Caring for Patients With Hemophilia A in the Midst of a Therapeutic Revolution

Slideset Download

Download this summary slideset from a live webinar for expert guidance on optimizing factor replacement therapy, incorporating nonfactor therapy, and addressing adherence and comorbidities to improve clinical outcomes for patients with hemophilia A.

Released: December 21, 2021

Expiration: December 20, 2022

No longer available for credit.

Share

Faculty

Miguel A. Escobar

Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Division of Hematology
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Mark T. Reding

Mark T. Reding, MD

Professor of Medicine
Division of Hematology, Oncology, and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical Center
Minneapolis, Minnesota

Guy Young

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children's Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Genentech, a member of the Roche Group

Sanofi Genzyme

Takeda Pharma USA Inc Takeda Onc Co

Program Director Disclosure

Program Director

Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Division of Hematology
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Miguel A. Escobar, MD: consultant/advisor/speaker: Bayer, BioMarin, CSL Behring, HEMA Biologics, LFB, Magellan, Novo Nordisk, Pfizer, Regeneron, Roche/Genentech, Sanofi, Takeda.

Faculty Disclosure

Primary Author

Mark T. Reding, MD

Professor of Medicine
Division of Hematology, Oncology, and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical Center
Minneapolis, Minnesota

Mark T. Reding, MD: researcher (paid to institution): Bayer, Biomarin; consultant/advisor/speaker: Bayer, Biomarin, CSL Behring, Genentech, HEMA Biologics, Novo Nordisk, Sanofi, Spark, Takeda.

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children's Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Guy Young, MD: consultant/advisor/speaker: BioMarin, Centessa, CSL Behring, Genetech/Roche, Hema Biologics, Novo Nordisk, Octapharma, Pfizer, Sanofi, Spark, Takeda.